公开(公告)号：US12246030B2

公开(公告)日：2025-03-11

申请号：US18167984

申请日：2023-02-13

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  Tirtha Chakraborty ,  Gilles Besin ,  Ruchi Jain

IPC: C07H21/04 ,  A61K9/00 ,  A61K9/127 ,  A61K31/7115 ,  C12N15/113 ,  C12N15/67

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20180028664A1

公开(公告)日：2018-02-01

申请号：US15674872

申请日：2017-08-11

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: A61K47/10 ,  C12N15/117 ,  A61K39/39 ,  C08G65/333 ,  C08G65/332 ,  C08G65/335 ,  A61K31/713 ,  C08G65/334

CPC classification number: A61K48/0033 ,  A61K9/127 ,  A61K31/7115 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  A61K47/543 ,  A61K47/544 ,  A61K47/60 ,  A61K47/6929 ,  A61K48/0066 ,  A61K2039/55555 ,  C08G65/3322 ,  C08G65/3326 ,  C08G65/33306 ,  C08G65/3331 ,  C08G65/33317 ,  C08G65/33324 ,  C08G65/3348 ,  C08G65/3356 ,  C08G2650/04 ,  C12N15/117 ,  C12N15/88 ,  C12N2310/141 ,  C12N2310/17 ,  C12N2320/32

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US11590157B2

公开(公告)日：2023-02-28

申请号：US17036374

申请日：2020-09-29

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  Tirtha Chakraborty ,  Gilles Besin ,  Ruchi Jain

IPC: C07H21/02 ,  A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20180147298A1

公开(公告)日：2018-05-31

申请号：US15674107

申请日：2017-08-10

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: A61K48/00 ,  A61K47/69 ,  A61K47/60 ,  A61K47/54

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US20190117798A1

公开(公告)日：2019-04-25

申请号：US16229509

申请日：2018-12-21

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: A61K48/00 ,  C12N15/88 ,  A61K47/10 ,  A61K47/54 ,  A61K31/7115 ,  A61K9/127 ,  A61K47/69 ,  A61K47/60 ,  A61K39/39 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117 ,  A61K31/713

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US10207010B2

公开(公告)日：2019-02-19

申请号：US15674872

申请日：2017-08-11

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: C12N15/88 ,  A61K9/127 ,  A61K48/00 ,  A61K47/54 ,  A61K47/69 ,  A61K47/60 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117 ,  A61K31/7115 ,  A61K39/00

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US11905525B2

公开(公告)日：2024-02-20

申请号：US16603111

申请日：2018-04-05

Applicant: ModernaTX, Inc.

Inventor： Luis Brito ,  Gilles Besin

IPC: C12N15/88 ,  A61K9/00 ,  A61K9/127 ,  A61K31/7105 ,  A61K47/12 ,  A61K47/28

CPC classification number: C12N15/88 ,  A61K9/0019 ,  A61K9/1271 ,  A61K31/7105 ,  A61K47/12 ,  A61K47/28 ,  C12N2310/141

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering nucleic acids in vivo. These compositions have reduced immune activation resulting in accelerated blood clearance and/or anti-drug antibodies and they have an improved toxicity profile and therapeutic index in vivo.

公开(公告)号：US20220265857A1

公开(公告)日：2022-08-25

申请号：US17583674

申请日：2022-01-25

Applicant: ModernaTX,Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: A61K48/00 ,  A61K9/127 ,  C12N15/88 ,  A61K31/7115 ,  A61K47/14 ,  A61K47/18 ,  A61K47/54 ,  A61K47/69 ,  A61K47/60 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US11285222B2

公开(公告)日：2022-03-29

申请号：US16599661

申请日：2019-10-11

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: A61K48/00 ,  A61K9/127 ,  C12N15/88 ,  A61K31/7115 ,  A61K47/14 ,  A61K47/18 ,  A61K47/54 ,  A61K47/69 ,  A61K47/60 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117 ,  A61K39/00

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US10849920B2

公开(公告)日：2020-12-01

申请号：US15761220

申请日：2016-10-05

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  Tirtha Chakraborty ,  Gilles Besin ,  Ruchi Jain

IPC: A61K48/00 ,  C07H21/04 ,  A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.